BRAF and melanoma: Our data clearly indicate that E2F1 inhibition potentiates the anti-proliferative and pro-apoptotic effects of BRAF inhibitors, PLX4032 and dabrafenib, in melanoma cell lines sensitive to BRAF inhibitor.